Boys Arnold & Co. Inc. Decreases Holdings in Johnson & Johnson (JNJ)

Boys Arnold & Co. Inc. trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 4.4% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 84,815 shares of the company’s stock after selling 3,906 shares during the period. Johnson & Johnson accounts for about 1.4% of Boys Arnold & Co. Inc.’s holdings, making the stock its 10th largest holding. Boys Arnold & Co. Inc.’s holdings in Johnson & Johnson were worth $11,220,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in JNJ. Sfmg LLC lifted its holdings in shares of Johnson & Johnson by 0.9% in the 2nd quarter. Sfmg LLC now owns 6,726 shares of the company’s stock valued at $890,000 after purchasing an additional 63 shares during the last quarter. Wechter Feldman Wealth Management Inc. lifted its holdings in shares of Johnson & Johnson by 1.4% in the 2nd quarter. Wechter Feldman Wealth Management Inc. now owns 1,841 shares of the company’s stock valued at $244,000 after purchasing an additional 26 shares during the last quarter. Prudential Financial Inc. lifted its holdings in shares of Johnson & Johnson by 7.8% in the 2nd quarter. Prudential Financial Inc. now owns 6,764,861 shares of the company’s stock valued at $894,923,000 after purchasing an additional 488,090 shares during the last quarter. Coho Partners Ltd. lifted its holdings in shares of Johnson & Johnson by 25.0% in the 2nd quarter. Coho Partners Ltd. now owns 692,243 shares of the company’s stock valued at $91,577,000 after purchasing an additional 138,599 shares during the last quarter. Finally, Great Lakes Advisors LLC lifted its holdings in shares of Johnson & Johnson by 11.9% in the 2nd quarter. Great Lakes Advisors LLC now owns 194,163 shares of the company’s stock valued at $25,686,000 after purchasing an additional 20,574 shares during the last quarter. 65.90% of the stock is owned by institutional investors.

Johnson & Johnson (NYSE:JNJ) traded down $0.97 on Tuesday, hitting $139.01. The company had a trading volume of 5,916,600 shares, compared to its average volume of 5,873,962. The firm has a market cap of $376,059.06, a PE ratio of 19.60, a P/E/G ratio of 2.85 and a beta of 0.80. The company has a current ratio of 1.32, a quick ratio of 1.02 and a debt-to-equity ratio of 0.36. Johnson & Johnson has a 1-year low of $109.32 and a 1-year high of $144.35.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share for the quarter, topping analysts’ consensus estimates of $1.80 by $0.10. The business had revenue of $19.65 billion for the quarter, compared to analysts’ expectations of $19.29 billion. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The company’s revenue was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.68 EPS. equities analysts expect that Johnson & Johnson will post 7.28 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 12th. Investors of record on Tuesday, November 28th will be paid a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 2.42%. The ex-dividend date is Monday, November 27th. Johnson & Johnson’s payout ratio is currently 58.33%.

Several equities analysts recently issued reports on the company. J P Morgan Chase & Co boosted their price target on Johnson & Johnson from $140.00 to $148.00 and gave the company an “overweight” rating in a research report on Wednesday, August 16th. Jefferies Group set a $145.00 price target on Johnson & Johnson and gave the company a “hold” rating in a research report on Tuesday, August 15th. Vetr cut Johnson & Johnson from a “hold” rating to a “sell” rating and set a $130.49 price target on the stock. in a research report on Monday, September 18th. Stifel Nicolaus boosted their price target on Johnson & Johnson from $140.00 to $142.00 and gave the company a “hold” rating in a research report on Wednesday, October 18th. Finally, Citigroup boosted their price target on Johnson & Johnson from $140.00 to $149.00 and gave the company a “buy” rating in a research report on Monday, October 23rd. Four investment analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have given a buy rating to the company’s stock. Johnson & Johnson currently has a consensus rating of “Hold” and a consensus target price of $144.59.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright laws. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2017/12/05/boys-arnold-co-inc-decreases-holdings-in-johnson-johnson-jnj.html.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply